Medical Tubing and Extrusion

Medical tubing and extrusion technologies

Abbott

Abbott earns FDA approval for new dual-energy ablation catheter

By

Abbott (NYSE: ABT) earned FDA approval for its new dual-energy catheter, TactiFlex Duo sensor-enabled ablation catheter. TactiFlex Duo joins Johnson & Johnson MedTech’s ThermoCool SmartTouch SF and Medtronic's Affera Sphere-9 catheter in the U.S. dual-energy ablation catheter market. Medtronic won its Sphere-9 approval in 2024, and J&J … [Read more...] about Abbott earns FDA approval for new dual-energy ablation catheter

Abbott gets FDA nod for longer length Esprit BTK drug-eluting scaffold

By

Abbott (NYSE:ABT) announced today that the FDA approved the longer length (76 mm) Esprit BTK drug-eluting scaffold system. The longer Esprit BTK system received approval for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD). CLTI can cause extreme pain, open wounds that don’t heal and, … [Read more...] about Abbott gets FDA nod for longer length Esprit BTK drug-eluting scaffold

Abbott data at HRS 2026 backs PFA, pacing systems

By

Abbott (NYSE:ABT) today shared new study findings supporting its pulsed field ablation (PFA) and conduction system pacing (CSP) systems. At Heart Rhythm Society (HRS) 2026 in Chicago, the company shared data from four trials backing the portfolios. Findings included six-month data from the FlexPulse IDE study evaluating the TactiFlex … [Read more...] about Abbott data at HRS 2026 backs PFA, pacing systems

Abbott has positive drug-eluting scaffold data

By

Abbott (NYSE:ABT) today shared promising 30-day results for its Esprit BTK everolimus-eluting resorbable scaffold system. Esprit features materials similar to dissolving sutures. Unlike metal stents, it’s not a permanent implant, providing support for blocked vessels only for a few months after the blockage is cleared. At that point, the vessel … [Read more...] about Abbott has positive drug-eluting scaffold data

Abbott completes enrollment in IVL study

By

An Abbott (NYSE:ABT) official said on social media that the company completed enrollment in a study of its intravascular lithotripsy (IVL) platform. SVP and President of Abbott Vascular, Julie Tyler, said on LinkedIn that the company's TECTONIC coronary IVL study conducted under FDA investigational device exemption (IDE) successfully completed … [Read more...] about Abbott completes enrollment in IVL study

Abbott earns CMS reimbursement win for Esprit drug-eluting scaffold

By

An Abbott (NYSE:ABT) official has shared a significant reimbursement win for its Esprit BTK drug-eluting scaffold system. On LinkedIn, SVP and President of Abbott Vascular, Julie Tyler, posted that the Centers for Medicare & Medicaid Services (CMS) approved transitional pass-through (TPT) payment status for Esprit BTK. TPT, a three-year … [Read more...] about Abbott earns CMS reimbursement win for Esprit drug-eluting scaffold

The biggest cardiac tech news out of the 2026 AF Symposium

By

Last week, the leading developers of treatments for atrial fibrillation (AFib) convened in Boston for the 2026 AF Symposium. At the event, the makers of technologies like pulsed field ablation (PFA) systems, left atrial appendage (LAA) devices, heart access catheters and more offered insights into how their therapies contribute to the treatment … [Read more...] about The biggest cardiac tech news out of the 2026 AF Symposium

Abbott studies support pulsed field ablation, dual ablation catheters

By

Abbott (NYSE: ABT) today announced new clinical data supporting its minimally invasive therapies for treating AFib. Results included 12-month findings supporting the Volt pulsed field ablation (PFA) system and positive outcomes with the TactiFlex Duo Ablation Catheter, Sensor Enabled (SE). Volt provides a single-catheter PFA approach to … [Read more...] about Abbott studies support pulsed field ablation, dual ablation catheters

Abbott picks up CE mark for TactiFlex dual-energy ablation catheter

By

Abbott (NYSE:ABT) Abbott (NYSE: ABT)+ announced today that it received CE mark for its TactiFlex Duo Ablation Catheter, Sensor-Enabled, to treat AFib. Following approval, the company also reported the first commercial cases using the catheter in Europe, completed this week. Dr. Isabel Deisenhofer, head of the department of Electrophysiology at … [Read more...] about Abbott picks up CE mark for TactiFlex dual-energy ablation catheter

Abbott earns FDA approval for Volt PFA system for AFib

By

Abbott (NYSE:ABT) announced today that the FDA approved its Volt pulsed field ablation (PFA) system to treat patients with AFib. The regulatory nod brings Abbott Volt to the U.S. PFA market to compete against the likes of Medtronic, Boston Scientific, Johnson & Johnson MedTech and Kardium. It follows CE mark approval for Volt earlier this … [Read more...] about Abbott earns FDA approval for Volt PFA system for AFib